Healthycaremaster Introduces HCM Ring for Non-Invasive Blood Glucose Monitoring and Women's Health Tracking
Hong Kong - Healthycaremaster (HCM) has announced the launch of the HCM Ring (Model: 2301B), a non-invasive blood glucose risk assessment smart ring. The device integrates BGEM (Blood Glucose Evaluation and Monitoring) technology, designed to assess blood glucose levels without the need for traditional finger-prick methods. Additionally, it includes features for tracking various health metrics, including menstrual cycles and pregnancy.
Development of Non-Invasive Blood Glucose Monitoring
The BGEM system has been developed in collaboration with Singapore's KK Women's and Children's Hospital. It utilizes machine learning and photoplethysmography (PPG) sensors to analyze blood glucose levels. The system has been tested against traditional glucometers, including the Accu-Chek Performa, in a study involving 500 participants, demonstrating an accuracy rate of 84.7%.
Unlike traditional blood glucose monitoring, which requires invasive procedures, the HCM Ring provides continuous, real-time risk assessment for blood glucose fluctuations. This allows users to track patterns and potential risks without the discomfort of frequent finger pricks.
Comprehensive Health Tracking Capabilities
The HCM Ring provides continuous health monitoring, including:
Heart Rate and Blood Oxygen Levels to support cardiovascular health assessments.
Heart Rate Variability (HRV) and Stress Monitoring to analyze physiological responses.
Activity and Sleep Tracking to provide data on daily movement and rest patterns.
Body Temperature Monitoring to detect fluctuations.
Designed for long-term use, the device is made from lightweight titanium alloy, ensuring durability while maintaining a sleek design. It features a battery life of 7-10 days with wireless charging for convenience.
Women's Health Tracking Features
The HCM Ring includes dedicated features for women's health, offering:
Menstrual Cycle Tracking, helping individuals monitor and predict cycle patterns.
Pregnancy Preparation Tools, assisting in tracking health metrics essential for conception planning.
Pregnancy Monitoring, offering real-time alerts and health updates throughout pregnancy.
These features enable users to set reminders and receive alerts for menstrual cycles, ovulation, and pregnancy-related health indicators. With a focus on accessibility and accuracy, the HCM Ring provides women with a tool to track and manage their reproductive health conveniently.
Advancements in Wearable Health Technology
Wearable health technology continues to evolve, and the HCM Ring represents a significant step toward non-invasive, data-driven personal health management. By combining BGEM technology with a range of vital health tracking capabilities, the device provides actionable insights that support overall well-being.
This integration of cutting-edge technology with user-friendly design aims to make health tracking more accessible for individuals managing blood glucose levels, general health, and reproductive health.
For additional details about the HCM Ring, visit Healthycaremaster's website.
About Healthycaremaster
Healthycaremaster (HCM) is a health technology company based in Hong Kong, dedicated to developing innovative solutions for personal health monitoring. The company focuses on integrating advanced technology with user-friendly designs to improve accessibility to health data. Through continuous research and development, HCM aims to provide individuals with reliable and non-invasive health management tools.
Country: HongKong
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
5 days ago
- Associated Press
Felycin®-CA1 (sirolimus delayed-release tablets) Redefines Feline Cardiac Care
First-in-class oral management option for hypertrophic cardiomyopathy earns FDA conditional approval, changing the landscape of feline medicine PENSACOLA, Fla., June 12, 2025 /PRNewswire/ -- Pegasus Laboratories/PRN Pharmacal has announced the addition of a new FDA conditionally approved drug, Felycin®-CA1 (sirolimus delayed-release tablets), to their portfolio. This first-in-class therapy is designed to manage ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM), representing a major milestone in feline medicine and offering new hope to owners of cats living with this progressive and often fatal disease. HCM is a heart condition which causes the muscular walls of a cat's heart to become abnormally thick, reducing the heart's ability to pump blood efficiently. This can lead to heart failure and other complications, including sudden death. Many cats with HCM remain subclinical for years, while others may develop symptoms of congestive heart failure. While the exact cause of the disease is not fully understood, HCM is more common in certain breeds, including British Shorthair, Chartreux, Maine Coon, Persian, Ragdoll, and Sphynx cats. Researchers have also identified mutations in various cardiac genes causing HCM in several of these breeds. 'Felycin-CA1 signals a turning point in feline medicine by providing veterinarians a much-needed option to help slow the progression of HCM beyond just managing the disease,' said Dr. Heather Davis, DVM, PhD, DACVS-LA, Director of Clinical Affairs and Veterinary Services at Pegasus Laboratories. 'It is a major step forward for cats and the people who care for them. For the first time, we're changing the conversation around what's possible in feline heart care.' FDA conditional approval of Felycin®-CA1 follows results from a multi-center study demonstrating its ability to improve key cardiac outcomes, while also proving its ease of use in everyday veterinary practices. 'Veterinarians have long-needed options beyond palliative care when it comes to feline HCM,' said Dr. Joshua Stern, DVM, PhD, DACVIM. 'With Felycin-CA1, we can offer a therapy that has been shown in our initial clinical trial to stop progressive heart muscle thickening, slowing disease progression. We believe this management option marks the beginning of a new chapter where innovation in feline therapeutics becomes the rule, not the exception.' Felycin®-CA1 is slated to be available beginning August 2025, in 0.4 mg, 1.2 mg, and 2.4 mg tablet strengths by prescription from a licensed veterinarian. Cats should be screened for pre-existing liver disease before starting the medication, and it should not be used in cats with pre-existing liver disease or diabetes mellitus. About Pegasus Laboratories Pegasus Laboratories, Inc., based in Pensacola Florida, is a pharmaceutical development and manufacturing organization focused on innovative products to treat chronic conditions in cats, dogs, and horses. Our products go to market under the PRN® Pharmacal brand. We also serve as a contract manufacturer for the Animal Health industry. We were founded in 1985 and acquired by PBI-Gordon Companies, Inc. in 1999. View original content to download multimedia: SOURCE Pegasus/PRN Pharmacal
Yahoo
5 days ago
- Yahoo
Felycin®-CA1 (sirolimus delayed-release tablets) Redefines Feline Cardiac Care
First-in-class oral management option for hypertrophic cardiomyopathy earns FDA conditional approval, changing the landscape of feline medicine PENSACOLA, Fla., June 12, 2025 /PRNewswire/ -- Pegasus Laboratories/PRN Pharmacal has announced the addition of a new FDA conditionally approved drug, Felycin®-CA1 (sirolimus delayed-release tablets), to their portfolio. This first-in-class therapy is designed to manage ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM), representing a major milestone in feline medicine and offering new hope to owners of cats living with this progressive and often fatal disease. HCM is a heart condition which causes the muscular walls of a cat's heart to become abnormally thick, reducing the heart's ability to pump blood efficiently. This can lead to heart failure and other complications, including sudden death. Many cats with HCM remain subclinical for years, while others may develop symptoms of congestive heart failure. While the exact cause of the disease is not fully understood, HCM is more common in certain breeds, including British Shorthair, Chartreux, Maine Coon, Persian, Ragdoll, and Sphynx cats. Researchers have also identified mutations in various cardiac genes causing HCM in several of these breeds. "Felycin-CA1 signals a turning point in feline medicine by providing veterinarians a much-needed option to help slow the progression of HCM beyond just managing the disease," said Dr. Heather Davis, DVM, PhD, DACVS-LA, Director of Clinical Affairs and Veterinary Services at Pegasus Laboratories. "It is a major step forward for cats and the people who care for them. For the first time, we're changing the conversation around what's possible in feline heart care." FDA conditional approval of Felycin®-CA1 follows results from a multi-center study demonstrating its ability to improve key cardiac outcomes, while also proving its ease of use in everyday veterinary practices. "Veterinarians have long-needed options beyond palliative care when it comes to feline HCM," said Dr. Joshua Stern, DVM, PhD, DACVIM. "With Felycin-CA1, we can offer a therapy that has been shown in our initial clinical trial to stop progressive heart muscle thickening, slowing disease progression. We believe this management option marks the beginning of a new chapter where innovation in feline therapeutics becomes the rule, not the exception." Felycin®-CA1 is slated to be available beginning August 2025, in 0.4 mg, 1.2 mg, and 2.4 mg tablet strengths by prescription from a licensed veterinarian. Cats should be screened for pre-existing liver disease before starting the medication, and it should not be used in cats with pre-existing liver disease or diabetes mellitus. About Pegasus Laboratories Pegasus Laboratories, Inc., based in Pensacola Florida, is a pharmaceutical development and manufacturing organization focused on innovative products to treat chronic conditions in cats, dogs, and horses. Our products go to market under the PRN® Pharmacal brand. We also serve as a contract manufacturer for the Animal Health industry. We were founded in 1985 and acquired by PBI-Gordon Companies, Inc. in 1999. View original content to download multimedia: SOURCE Pegasus/PRN Pharmacal Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Health Line
05-06-2025
- Health Line
How Does Hypertrophic Cardiomyopathy Look Inside the Body?
Hypertrophic cardiomyopathy (HCM) is a condition that thickens some of the heart's muscles, making it harder to pump blood. Hypertrophic cardiomyopathy (HCM) usually affects the ventricular septum, which is located between your right and left ventricles (the lower chambers of your heart). A thicker ventricular septum takes up more space and can affect blood flow, especially through the left ventricle. HCM is genetic, so if one person has the condition, others in the family should also get checked. Symptoms include fatigue, dizziness, shortness of breath, chest pain, or an irregular heart rate. Sometimes, there are no symptoms. HCM can be diagnosed with an echocardiogram, a test that shows an image of your heart. Other tests may also be needed. Over time, HCM can worsen, so managing the condition is important. Many people with HCM take medications to manage their symptoms, while some need surgeries or procedures to improve blood flow through the heart. Explore what a typical heart looks like versus what it looks like with HCM in the interactive experience below.
